MedTrace Logo

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

NCT01144897 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-10-02

No results posted yet for this study

Summary

One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material \[C-11\] acetate, will be helpful in detecting prostate cancer lesions in subjects with castrate-resistant prostate cancer (CRPC). This PET scan will be combined with a computed tomography (CT) scan taken during the same imaging session. The other purpose of the PET-CT scan using \[C-11\] acetate (PET Acetate Scan) is to assist in identifying who is responding to the treatment (docetaxel chemotherapy).

Conditions

Interventions

RADIATION

PET Acetate scan

PET Acetate scans will be done to detect prostate cancer lesions.

DRUG

Carbon-11 labeled Acetate

C-11 Acetate is a radiotracer used in PET scanning

Sponsors & Collaborators

  • Daniel Vaena

    lead OTHER

Principal Investigators

  • Daniel Vaena, MD · University of Iowa

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-11-30
Completion
2018-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144897 on ClinicalTrials.gov